AstraZeneca Announces First Patient Enrolled in Head-to-Head Comparison of CRESTOR/Ezetimibe With Simvastatin/Ezetimibe
London (ots/PRNewswire)
AstraZeneca today announced enrolment of
the first patient in the new GRAVITY study (Gauging the lipid effects
of RosuvAstatin plus ezetimibe Versus sImvastatin plus ezetimibe
TherapY). GRAVITY is a clinical trial examining the impact on
LDL-cholesterol ('bad' cholesterol) levels in patients with
hypercholesterolaemia and coronary heart disease following a
treatment regimen with lower doses of CRESTOR plus ezetimibe,
compared to higher doses of simvastatin plus ezetimibe (in a fixed
dose combination marketed as Vytorin(TM) or Inegy(TM)). Ezetimibe is
a cholesterol absorption inhibitor and this study is AstraZeneca's
first head-to-head comparison of CRESTOR/ezetimibe with
simvastatin/ezetimibe.CRESTOR provides comprehensive dyslipidaemia management, offering the most effective LDL-C reduction of any statin available, with the additional benefit of raising HDL across the dose range.
In a previous clinical trial, EXPLORER, CRESTOR 40mg with ezetimibe 10mg helped high risk patients achieve unprecedented levels of LDL-C reduction of up to 70% compared to 57% with CRESTOR alone.
"GRAVITY will, for the first time, examine the effects of adding ezetimibe to low dose CRESTOR and to simvastatin in a head-to-head clinical trial setting, to see which of these treatment options achieves the greatest LDL-C lowering benefits. We expect these results to firmly establish CRESTOR as the best statin upon which to base any combination therapy for patients with dyslipidaemia," said Elisabeth Björk, Global Medical Science Director for CRESTOR.
GRAVITY is a 12-week, open-label, randomised, parallel-group, multicentre, Phase IIIb study of 800 patients to compare the efficacy and safety of CRESTOR (rosuvastatin) 10mg and 20mg in combination with ezetimibe 10mg and simvastatin 40mg and 80mg in combination with ezetimibe 10mg in patients with hypercholesterolaemia and coronary heart disease (CHD) or a CHD risk equivalent, atherosclerosis or a 10-year CHD Risk of >20%. Complete results are due in 2009.
GRAVITY is a part of AstraZeneca's extensive GALAXY clinical trials programme, designed to address important unanswered questions in statin research and to investigate the impact of CRESTOR on cardiovascular risk reduction and patient outcomes. Currently, more than 69,300 patients have been recruited from 55 countries worldwide to participate in the GALAXY Programme.
CRESTOR has now received regulatory approvals in over 90 countries across five continents. Over 11 million patients have been prescribed CRESTOR worldwide. Data from clinical trials and real world use shows that the safety profile for CRESTOR is in line with other marketed statins.
The 40 mg dose is the highest registered dose of CRESTOR. CRESTOR should be used according to the prescribing information, which contains recommendations for initiating and titrating therapy according to the individual patient profile. In most countries, the usual starting dose of CRESTOR is 5mg or 10mg. The 40mg dose should be reserved for patients with severe hypercholesteraemia at high cardiovascular risk.
Note to Editors
This press release has been made available on worldwide press communication media for the benefit of correspondents writing for the medical professional press. Differing national legislation, codes of practice, medical practice etc mean that you should contact your local AZ press office to obtain information designed for use in your country. In particular this press release has not been prepared for use in the USA.
For further information please visit: http://www.AstraZenecaPressOffice.com
Contact:
Contact: Ben Strutt, Global PR Manager, Cardiovascular Therapy Area,
AstraZeneca, Tel: +44-1625-230076, Mob: +44-7919-565990, Email:
ben.strutt@astrazeneca.com